Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) Shares Outstanding (Weighted Average): 2019-2024

Historic Shares Outstanding (Weighted Average) for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $70.8 million.

  • Nurix Therapeutics' Shares Outstanding (Weighted Average) rose 18.69% to $76.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was $76.4 million, marking a year-over-year increase of 18.69%. This contributed to the annual value of $70.8 million for FY2024, which is 46.04% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Shares Outstanding (Weighted Average) of $70.8 million as of FY2024, which was up 46.04% from $48.5 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Shares Outstanding (Weighted Average) registered a high of $70.8 million during FY2024, and its lowest value of $38.9 million during FY2020.
  • Over the past 3 years, Nurix Therapeutics' median Shares Outstanding (Weighted Average) value was $48.5 million (recorded in 2023), while the average stood at $55.5 million.
  • Data for Nurix Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 46.04% (in 2024) over the last 5 years.
  • Over the past 5 years, Nurix Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $38.9 million in 2020, then rose by 14.82% to $44.6 million in 2021, then climbed by 5.96% to $47.3 million in 2022, then rose by 2.60% to $48.5 million in 2023, then skyrocketed by 46.04% to $70.8 million in 2024.